Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Weight-loss jabs have grown massively in popularity over the past year, but a team of scientists has now found that the ...

Indian pharmaceutical companies are preparing to flood the market with generic versions of Novo Nordisk’s semaglutide—sold ...

Most importantly, don’t leave nutrition and exercise out of the equation. There is a huge difference between a healthy and an unhealthy thin person.

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 receptor agonists semaglutide or tirzepatide, at the end of two years, ...

U nless you’ve been living under a rock, you’ve probably heard the buzz about weight-loss drugs like Ozempic. Some people ...

A new study suggests that popular weight-loss injections like Wegovy and Mounjaro don't deliver the same dramatic results in ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average.

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...